𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hyperhomocysteinemia recurrence in levodopa-treated Parkinson’s disease patients

✍ Scribed by V. Belcastro; L. Pierguidi; A. Castrioto; C. Menichetti; G. Gorgone; R. Ientile; F. Pisani; A. Rossi; P. Calabresi; N. Tambasco


Book ID
111066219
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
95 KB
Volume
17
Category
Article
ISSN
1351-5101

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Hyperhomocysteinemia in levodopa-treated
✍ Stefano Zoccolella; Claudia dell'Aquila; Giovanni Abruzzese; Angelo Antonini; Ub 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was

Cysteine elevation in levodopa-treated p
✍ Thomas Müller; Wilfried Kuhn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

## Abstract Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cystei

Mortality of patients with parkinson's d
✍ R. J. Marttila; U. K. Rinne; T. Siirtola; V. Sonninen 📂 Article 📅 1977 🏛 Springer 🌐 English ⚖ 372 KB

The effect of levodopa on the mortality of patients with Parkinson's disease was investigated in 349 patients treated with levodopa or levodopa combined with decarboxylase inhibitor during 1969-1975 inclusive. During the study period, 61 patients died. The expected mortality was 32.99 resulting in a